Nathan Frey
Also known as Nathan C. Frey
Nathan Frey is a machine learning researcher who applies generative models to drug discovery and protein design. A materials scientist by training, he earned a PhD at the University of Pennsylvania as a National Defense Science and Engineering Graduate Fellow, did a postdoctoral fellowship at MIT, and published Neural scaling of deep chemical models in Nature Machine Intelligence in 2023. As a group leader at Genentech's Prescient Design, he and twelve coauthors won an ICLR 2024 Outstanding Paper award for Protein Discovery with Discrete Walk-Jump Sampling. He co-founded the biotech startup Coefficient Bio in 2025, and Anthropic acquired it in April 2026. He leads drug discovery and development research at Anthropic.
Timeline
-
By 2019
Penn PhD and 2D materials
He does a PhD in Materials Science and Engineering at the University of Pennsylvania as a National Defense Science and Engineering Graduate Fellow. In 2019, he leads a study in Vivek Shenoy's group, published in ACS Nano, that uses positive-and-unlabeled machine learning to predict 18 MXene compounds as candidates for synthesis.
-
2023
Neural scaling of chemical models
A postdoctoral fellow at MIT, he is first author of Neural scaling of deep chemical models, written at MIT Lincoln Laboratory with Rafael Gómez-Bombarelli, Connor Coley, Vijay Gadepally and others. Nature Machine Intelligence publishes it in 2023; it finds a scaling exponent of 0.17 for chemical language models on the largest dataset studied.
-
By 2024
Group leader at Prescient Design
By 2024, he is a Principal Machine Learning Scientist and Group Leader at Prescient Design, Genentech. His work there covers lab-in-the-loop therapeutic antibody design, discrete diffusion, interpretability, and foundation models for drug discovery.
-
2024
An ICLR Outstanding Paper award
In 2024, he and twelve coauthors, including Kyunghyun Cho and Saeed Saremi, win an ICLR Outstanding Paper award for Protein Discovery with Discrete Walk-Jump Sampling. The method learns a smoothed energy function, samples it with Langevin MCMC, and returns to the data with one-step denoising; in laboratory tests of antibody designs, 97-100% of generated samples are expressed and purified.
-
2025
Co-founding Coefficient Bio
He co-founds Coefficient Bio in 2025, a New York biotech AI startup that works in stealth with a team smaller than ten people, and serves as its CTO.
-
April 2026
Anthropic acquires Coefficient Bio
In April 2026, Anthropic acquires Coefficient Bio in an all-stock deal reported at about $400 million. The team of fewer than 10 people joins Anthropic's healthcare and life sciences division.
-
As of October 2026
Drug discovery research at Anthropic
He leads drug discovery and development research at Anthropic. His team is building a "pipeline-in-a-person" so that one biotech operator and a number of Claudes can create and operate drug programs, with the aim of making Claude the best model for biotech.
Career
- Since 2026AnthropicDrug discovery and development research lead
- From 2025Coefficient BioCo-founder and CTO
- Massachusetts Institute of TechnologyPostdoctoral Fellow
- RochePrincipal Machine Learning Scientist and Group Leader
Education
- University of PennsylvaniaPhD in Materials Science and Engineering
Sources and credits
Photo: We have no published photo of Nathan Frey yet. Send us a free-licensed photo.
- Nathan C. Frey
- Penn Engineers: New Machine Learning Approach Predicts Which 2D Materials Can Be Synthesized | Penn Engineering
- Neural scaling of deep chemical models | Nature Machine Intelligence
- Computer Vision News - June 2024 – Page 8
- ICLR 2024 Awards
- Anthropic moves deeper into biotech with reported Coefficient Bio deal - TechInformed
- Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People | BiopharmaTrend
- Anthropic just paid $400 million for a startup with fewer than 10 people

